Salomon Azoulay

CIK: 0002030246

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (44.4%)

Position reduction

Option Exercises (M)2 (22.2%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MBX

MBX Biosciences, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

MBX
MBX Biosciences, Inc.
Aug 4, 2026
Sale(S)
Direct
370 shares at avg. $65.77$24K
MBX
MBX Biosciences, Inc.
May 8, 2026
Exercise(M)
Direct
55K shares at avg. $10.46$575K
MBX
MBX Biosciences, Inc.
May 8, 2026
Sale(S)
Direct
55K shares at avg. $38.38$2.1M
MBX
MBX Biosciences, Inc.
May 8, 2026
Exercise(M)
Direct
15K shares at avg. $16.00$240K
MBX
MBX Biosciences, Inc.
May 8, 2026
Sale(S)
Direct
15K shares at avg. $38.30$575K
MBX
MBX Biosciences, Inc.
May 6, 2026
Sale(S)
Direct
231 shares at avg. $29.54$7K
MBX
MBX Biosciences, Inc.
Feb 2, 2026
Award(A)
Direct
15K shares-
MBX
MBX Biosciences, Inc.
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
90K shares-
MBX
MBX Biosciences, Inc.
Sep 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
45K shares-

		Type	Shares	Price		Ownership
Aug 4, 2026	MBX MBX Biosciences, Inc.	Sale(S)	370	$65.77	$24,335	Direct
May 8, 2026	MBX MBX Biosciences, Inc.	Exercise(M)	55,000	$10.46	$575,300	Direct
May 8, 2026	MBX MBX Biosciences, Inc.	Sale(S)	55,000	$38.38	$2,110,900	Direct
May 8, 2026	MBX MBX Biosciences, Inc.	Exercise(M)	15,003	$16.00	$240,048	Direct
May 8, 2026	MBX MBX Biosciences, Inc.	Sale(S)	15,003	$38.30	$574,615	Direct
May 6, 2026	MBX MBX Biosciences, Inc.	Sale(S)	231	$29.54	$6,824	Direct
Feb 2, 2026	MBX MBX Biosciences, Inc.	Award(A)	15,000	-	$0	Direct
Feb 3, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	90,000	-	-	Direct
Sep 12, 2024	MBX MBX Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	45,011	-	-	Direct

1-9 of 9 transactions

About Azoulay Salomon

Azoulay Salomon (SEC CIK 0002030246) files insider reports with the SEC as Chief Medical Officer of MBX Biosciences, Inc. (MBX).

Signal8 holds 7 ownership filings by Azoulay Salomon (1 Form 3, 6 Form 4), filed between Sep 12, 2024 and Aug 5, 2026. Those filings report 9 transactions, from Sep 12, 2024 to Aug 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Azoulay Salomon's filings is in CARMEL, IN.

Recent filings by Azoulay Salomon

Aug 4, 2026: Open-market sale of MBX shares (Form 4, code S).
May 8, 2026: Option exercise of MBX shares (Form 4, code M).
May 8, 2026: Open-market sale of MBX shares (Form 4, code S).
May 8, 2026: Option exercise of MBX shares (Form 4, code M).
May 8, 2026: Open-market sale of MBX shares (Form 4, code S).

Other insiders filing for MBX Biosciences, Inc. (MBX)

Radovich Peter, Director
Smither John W, Chief Financial Officer
Hoerter Steven L., President and CEO
Mathers Edward T, Director
Pescovitz Ora H., Director
Heron Patrick J, Director

How to read Form 4 transaction codes